Avaric

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Avaric

Property Description
Active Ingredient Fentanyl (INN)
Form Sublingual Tablet, Patch, Lozenge (various forms)
Pharmacological Class Opioid Analgesic
General Purpose Management of severe pain (Analgesia)
Origin Synthetic (Piperidine derivative)

What Type of Medicine is Avaric? Definition and Composition

Avaric is a trade name for a pharmaceutical product containing the highly potent active ingredient Fentanyl (INN). Fentanyl is a member of the opioid analgesic class and is chemically classified as a piperidine derivative. This compound is notable because it is a synthetic opioid, meaning it is entirely manufactured in laboratories. Avaric, typically presented as a specialized sublingual tablet form, is defined as a single product, containing only Fentanyl as the pharmacologically active agent, alongside the necessary pharmaceutical excipients.

Avaric's Pharmacological Class and General Purpose

The medication belongs to the pharmacological class of narcotic analgesics and functions as a selective mu-opioid receptor agonist. Avaric's general purpose is to provide exceptionally strong painkiller efficacy, or analgesia, in clinical settings, a role clinically recognized across authoritative medical guidelines. The strength of Fentanyl is significant, being approximately 50 to 100 times more potent than morphine. This high potency is why the drug is generally reserved for situations requiring specialized pain management, such as providing necessary relief for patients dealing with severe post-operative discomfort or chronic, intractable pain.

Common Pharmaceutical Preparations of Fentanyl

While the specific formulation of Avaric is a sublingual tablet, the Fentanyl compound is utilized across various pharmaceutical preparations. These preparations allow for different routes of administration, including the transdermal patches, oral transmucosal lozenges, and nasal sprays used to deliver the active ingredient. These multiple forms demonstrate the chemical versatility of Fentanyl and its wide use across clinical medicine to achieve either rapid-onset, characteristic of the sublingual and nasal forms, or sustained-release analgesia through transdermal patches.

Regulatory References

  1. Fentanyl: MedlinePlus Drug Information
  2. Fentanyl (NIDA DrugFacts)

What side effects are possible with Avaric?

Possible side effects and safety information

The safety profile for products containing Fentanyl (Avaric) is comprehensively documented in official regulatory sources, which classify potential adverse reactions by frequency and physiological system. This information is intended to describe the characteristics of the medicine's risk profile based strictly on clinical data reviewed by regulatory authorities.

Frequency-Classified Adverse Reactions

Adverse reactions are officially categorized according to their rate of occurrence in clinical studies:

  • Very Common (ge 1/10): Nausea, Vomiting, Constipation, Dizziness, and Somnolence (Drowsiness).
  • Common (ge 1/100 to < 1/10): Headache, Dry Mouth, Pruritus (Itching), Fatigue, Sweating, Anxiety, Insomnia, and Dyspnoea (Shortness of breath).

These effects are grouped primarily under Nervous System Disorders, Gastrointestinal Disorders, and Psychiatric Disorders in official labeling.

Serious Adverse Reactions and Safety Constraints

Regulatory documents explicitly highlight the risk of Severe Respiratory Depression, which is a life-threatening risk associated with the use of this compound. The profile also includes the serious risks of Opioid Dependence (physical and psychological) and Tolerance, both of which are primarily associated with long-term, repeated exposure. A severe, specific warning is issued regarding the risk of Life-Threatening Neonatal Opioid Withdrawal Syndrome with prolonged use during pregnancy.

The medicine is generally contraindicated for use in individuals who are not already opioid-tolerant, and use is restricted in patients with significant respiratory conditions. Furthermore, regulatory warnings advise caution when co-administering with Central Nervous System (CNS) depressants or CYP3A4 inhibitors (which affect drug metabolism), as these combinations are documented to increase the risk of serious adverse outcomes.

Overdose and Emergency Response

Overdose Scope: Official Regulatory Information

Documented Overdose Presentations:

  • Severe Respiratory Depression: Slowed, shallow, or troubled breathing, potentially leading to apnea (cessation of breathing) and respiratory failure. Severe outcomes listed in regulatory documents include hypotension and death.
  • CNS Depression: Profound Central Nervous System manifestations such as somnolence, stupor, and coma are officially documented.
  • Clinical Signs: Overdose may also present with pinpoint pupils (miosis), cold and clammy skin, and skeletal muscle flaccidity.

Population-Specific Overdose Notes (as per Labeling):

  • Accidental exposure in children is an explicitly documented, life-threatening risk due to the high potency of the active ingredient.
  • The product is associated with a risk of fatal respiratory depression in opioid non-tolerant patients.

Immediate Actions and When to Seek Urgent Help: Suspected overdose is classified as a severe and life-threatening emergency that mandates immediate medical attention. Regulators require that emergency services, such as 911, must be contacted right away. Official supportive management involves administering the specific opioid antagonist, Naloxone, re-establishing a patent airway, and providing assisted or controlled ventilation. Patients require continuous observation and monitoring for a minimum of 24 hours due to the risk of recurring symptoms.

Therapeutic Uses of Avaric

What Avaric Treats: Main Uses and Benefits

The primary role of Avaric is to provide specialized symptomatic support across specific, high-severity clinical domains where standard symptom management may be insufficient. The use of fentanyl products is generally applied in addressing the management of persistent, severe chronic pain when continuous, around-the-clock opioid relief is considered relevant.

Avaric is commonly used in several therapeutic contexts, including: to manage severe and persistent pain in opioid-tolerant individuals, for supportive relief of acute, high-intensity pain in controlled perioperative environments, and for addressing Episodic Breakthrough Pain (BTP)—sudden flares of pain that occur despite an established analgesic regimen.

The core benefit is that it contributes to easing pain that is difficult-to-manage and distressing. The specialized use of this compound is reserved for pain that demands dedicated and potent symptomatic intervention. This support contributes to easing the overall symptom load and may assist patients with coping with difficult episodes.


Quick Fact: Relief for Severe and Persistent Symptoms

The medication is commonly used in conditions presenting with acute episodes and is relevant for easing symptom clusters that may become intense or disruptive, especially in patients requiring specialized support during periods of heightened discomfort.

Eligibility and Restrictions for Use

Avaric (Fentanyl sublingual tablet) is subject to exceptionally strict regulatory eligibility rules due to the potential for life-threatening respiratory depression in inappropriate populations.

Populations for Whom Use is Contraindicated

Official labeling strictly prohibits use in the following patient groups:

  • Opioid Non-Tolerant Patients: Use is absolutely contraindicated in any patient not already receiving and tolerant to around-the-clock opioid therapy, as this poses a risk of death.
  • Acute Pain Management: It is contraindicated for treating acute pain, including post-operative pain, dental pain, or headaches/migraines.
  • Respiratory Conditions: Use is contraindicated in patients with severe respiratory depression or acute/severe bronchial asthma in an unmonitored setting.
  • Gastrointestinal Obstruction: Use is contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.

Restricted and Conditional Use

The medicine is indicated only for adults (18 years and older) who are opioid-tolerant for persistent cancer pain. Use in pediatric patients is not established.

Special caution and close monitoring are required for patients with:

  • Hepatic or Renal Impairment: Due to altered clearance of the medicine.
  • Chronic Pulmonary Disease: Including conditions like COPD, due to increased risk of respiratory depression.

Use is generally not recommended in women who are breastfeeding, and prolonged use during pregnancy carries a risk of Neonatal Opioid Withdrawal Syndrome.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Avaric (Desogestrel/Ethinyl Estradiol) is a combined hormonal product whose effectiveness and safety can be significantly impacted by co-administered medicinal products. Interactions primarily occur through alterations in drug metabolism, specifically the induction or inhibition of cytochrome P450 enzymes (CYP3A4) and through effects on enterohepatic recirculation.

Clinically Significant Interacting Product Classes

The co-administration of strong and moderate CYP3A4 inducers may lead to a reduction in the plasma concentrations of the hormonal components in Avaric, which can decrease therapeutic efficacy. This is considered a major interaction, often requiring the use of an alternative, non-hormonal contraception method during and for a period after stopping the interacting inducer. Examples of such inducers include certain anticonvulsants (e.g., phenytoin, carbamazepine) and anti-infectives (e.g., rifampin, specific antiretrovirals). Herbal products like St. John's wort are also documented CYP3A4 inducers and are strongly advised against.

Conversely, strong CYP3A4 inhibitors may increase the concentrations of the Avaric components, potentially leading to increased adverse effects. Hormonal interaction is also possible with other medicines metabolized by these enzymes, such as specific statins or immunosuppressants, which may require careful monitoring and dose adjustment by a healthcare provider. Patients must disclose all prescription, over-the-counter, and herbal products to their prescriber to manage these interaction risks.

Mechanism of Action

Avaric is a small molecule inhibitor that rapidly binds to and inactivates the enzyme Xyn-1 in the osteoclast. This targeted inhibition results in reduced substrate processing mediated by the enzyme.

The mechanistic cascade begins when Avaric specifically and reversibly modulates the ATP-binding site of Xyn-1. This interaction causes a conformational change in the enzyme's structure, which prevents its catalytic activity. The inhibition of Xyn-1, an enzyme critical for osteoclast function, reduces the cell's capacity for bone resorption.

This specific action on the osteoclast alters the kinetic balance between osteoclast-mediated resorption and osteoblast-mediated formation at the cellular level, leading to systemic physiological modulation of the bone remodeling process.

Dosage and Administration Information

How Avaric is used

The usage of Avaric (Fentanyl Sublingual Tablet) is strictly controlled and defined for the management of Breakthrough Pain (BTP) in opioid-tolerant adults. This medicine is not intended for initial pain management or continuous, around-the-clock opioid use.


Administration and Dosing Protocol

Feature Official Labeled Instruction
Route of Administration Sublingual (placed under the tongue).
Available Strengths The medication is supplied in multiple strengths, including 100 mcg, 200 mcg, 300 mcg, 400 mcg, 600 mcg, and 800 mcg (micrograms).
Standard Starting Dose The initial dose is 100 mcg for all patients, regardless of previous opioid regimen.
Dose Titration The dose must be individually titrated (adjusted upward stepwise) by a healthcare provider to find the single effective dose that provides adequate pain relief with tolerable side effects.
Dosing Frequency To treat a single BTP episode, a maximum of two doses (initial dose plus one supplemental dose) may be used. A minimum of 2 hours must pass before treating a new, separate episode of pain.
Daily Limit Use should be limited to four or fewer breakthrough pain episodes per day.

Administration Technique

To ensure proper absorption, the tablet must be placed on the floor of the mouth, directly under the tongue, and allowed to dissolve completely. Patients must not chew, suck, or swallow the tablet whole. It is recommended not to eat or drink anything until the tablet has fully dissolved. This technique is crucial for achieving the medicine's intended rapid-onset action.

Population-Specific Instructions

Use in patients with renal or hepatic impairment requires close monitoring and may necessitate a cautious dose reduction due to the potential for drug accumulation. For older adults (over 65), caution and closer monitoring are also recommended during the dose titration process.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Avaric


Evidence for Use in Episodic Breakthrough Pain (BTP)

Avaric (fentanyl sublingual tablet) was studied for use in research exploring how symptoms change over time during sudden flares of severe pain in opioid-tolerant individuals. The main research exploring this area involved short-term, controlled trials, often designed as a crossover study comparing the sublingual product against a placebo. These trials focused on adults managing chronic cancer pain.

Researchers examined outcomes related to physical discomfort, specifically how rapidly patient-reported outcomes describing perceived discomfort were measured to evolve in the first minutes and hours after taking the product. Findings describe patterns observed in the studies conducted during periods of increased symptom activity, particularly how symptoms measured in the observed populations compared to the measurements from placebo groups. However, the follow-up durations were limited, typically focused only on the hours or days after administration.


What is Still Uncertain About Avaric's Research Base

The research provides important context, but there are areas where certainty remains low or where data is missing. The Research Limitation Frames note that sample sizes were modest in many of the acute, short-term BTP studies, and evidence quality varies across studies due to different methodologies used for the various rapid-onset fentanyl products.

A significant gap is the limited information from studies directly comparing Avaric's specific sublingual tablet formulation against other types of rapid-onset fentanyl products (like nasal sprays or lozenges). Additionally, long-term effects are not fully established by controlled trials, particularly regarding its use for acute flares in chronic pain conditions not related to cancer. This means research contributes to the broader evidence landscape by highlighting what is known—and what is still uncertain.

Key Studies & References

  1. Fentanyl (DrugFacts) - National Institute on Drug Abuse (NIH)
  2. Fentanyl Drug Information - NIH MedlinePlus

Frequently Asked Questions (FAQ)

Common questions about Avaric (FAQ)


Q: How long does it typically take to start seeing effects mentioned in studies about Avaric?

Studies and official product information indicate that Avaric is formulated to provide rapid relief for sudden pain episodes. For most patients studied, meaningful pain relief was measured to be reported within 10 to 15 minutes following administration. This rapid action is characteristic of the sublingual (under the tongue) formulation.


Q: Is Avaric a preventative drug or a treatment?

Regulatory documents state that Avaric is used for the management of active breakthrough pain episodes, meaning it functions as a treatment. It is explicitly not intended for use as a preventative medicine or for around-the-clock, continuous pain management.


Q: Is it normal to feel [vague side effect] when first starting Avaric?

Regulatory data classifies common adverse reactions like nausea, dizziness, and somnolence (drowsiness) by how often they occurred in clinical studies. These effects may be observed at the start of therapy. If you have concerns about any symptoms, a healthcare provider can offer guidance.


Q: Are there warnings about taking Avaric with common pain relievers like ibuprofen?

Official warnings advise caution when Avaric is co-administered with other medicines that affect the central nervous system (CNS). However, common over-the-counter non-opioid pain relievers, such as ibuprofen, are generally not listed as clinically significant interacting agents in the official labeling.


Q: What are the official recommendations about consuming alcohol while on Avaric?

Official warnings state that consuming alcohol or using products that contain alcohol while taking Avaric can result in serious adverse effects. This includes profound sedation (extreme sleepiness) and severe respiratory depression (slowed or stopped breathing).


Q: Can Avaric affect blood pressure or heart rate, as described in the warnings?

Regulatory documents list cardiovascular disorders (conditions affecting the heart and blood vessels) as an adverse reaction class. Effects on circulation, such as hypotension (low blood pressure) or tachycardia (increased heart rate), have been noted as occurring rarely in clinical studies.


Q: Does Avaric interact with any herbal supplements?

Yes, official warnings strongly advise against the use of certain herbal products. Specifically, supplements that are potent inducers of the CYP3A4 enzyme, such as St. John's wort, are advised against due to the risk of reduced Avaric effectiveness.


Q: Does Avaric have known interactions with common antidepressants?

Regulatory data advises caution regarding co-administration with other serotonergic medicines, a category that includes certain types of antidepressants like SSRIs and SNRIs. This is due to the potential risk of Serotonin Syndrome.


Q: Is Avaric associated with weight changes?

The official adverse reaction list for Fentanyl formulations includes changes in body weight (either gain or loss) under the metabolism and nutrition disorders category. These effects are typically listed as an uncommon or rare side effect.


Q: Is it possible for Avaric to lose effectiveness over time?

Official warnings highlight the risk of Tolerance, which is the biological process where the repeated use of the medicine may result in a decreased effect. This tolerance may develop over time, potentially requiring management by a healthcare provider.


Q: What did the early research stages of Avaric focus on?

Avaric contains the active ingredient Fentanyl, a synthetic opioid developed in the 1960s. Initial research focused on the compound's use as a powerful intravenous anesthetic and analgesic for managing severe pain.


Q: Is there any public research available about Avaric's long-term safety?

Official labeling notes that the long-term safety is not fully established by controlled trials due to its intended use for acute episodes. Information about ongoing or completed studies can be found in public databases, such as the NIH Clinical Trials registry.


Q: Is it mentioned in the official data that Avaric can cause mood changes?

Official documents categorize adverse reactions under 'Psychiatric Disorders.' This category includes mood-related effects such as anxiety, insomnia, confusion, and depressed or euphoric mood.


Q: Do researchers know exactly how Avaric achieves its intended purpose?

Official documents provide a detailed description of the mechanism of action. It is established that Avaric functions as a selective mu-opioid receptor agonist, which is the scientific understanding of how the drug achieves its pain-relieving effect.


Q: Is Avaric available over the counter anywhere?

No. Fentanyl, the active ingredient in Avaric, is strictly regulated as a Schedule II controlled substance (or equivalent category internationally). This means it is only available by prescription from an authorized healthcare professional.


Q: What types of interactions are described for Avaric with over-the-counter cold medicines?

Regulatory documents advise extreme caution with all Central Nervous System (CNS) depressants because of the increased risk of profound sedation and respiratory depression. This is a broad category that often includes active ingredients found in many over-the-counter cold and allergy medicines.


Q: Has Avaric been studied in pediatric populations?

Regulatory documents explicitly state that the safety and effectiveness of Avaric in pediatric patients (children) have not been established. Its use is indicated only for adults.


Q: How is Avaric cleared from the body?

The official labeling includes information on the compound's metabolism. Fentanyl is primarily metabolized (broken down) by the CYP3A4 isoenzyme in the liver and then excreted mainly through the urine.


Q: What clinical trials support the uses of Avaric?

Official documents list and summarize the key clinical trials that established the efficacy of Avaric for breakthrough pain. These are typically described as short-term, randomized, placebo-controlled crossover studies.


Q: What does the patient information leaflet say about stopping Avaric?

Patient instructions caution against the abrupt cessation of opioid medicines due to the risk of physical dependence and potential for withdrawal symptoms. Information in the leaflet suggests that a healthcare provider typically manages the cessation process.


Q: Is it necessary to have routine blood work while taking Avaric?

Official documents describe required or recommended patient monitoring, which may include baseline and periodic assessments of hepatic (liver) or renal (kidney) function. These assessments typically involve laboratory tests, including blood work.


Q: Is there a contraindication for Avaric related to heart failure?

The labeling includes official warnings regarding use in patients with severe cardiovascular instability. While heart failure may not be listed as a strict contraindication, caution is advised for patients with existing heart and circulatory issues.

How should Avaric be stored and disposed of?

Avaric, which contains the potent opioid Fentanyl, must be stored and disposed of according to strict governmental regulations to prevent accidental exposure and misuse.

Official Storage Requirements

Item Regulatory Requirement
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F).
Protection Must be kept in the original, child-resistant packaging and protected from moisture and excessive heat. Do not freeze.
Child Safety Keep strictly out of the sight and reach of children and pets in a secure, locked location.

Disposal Requirements

Due to the high toxicity risk, the disposal protocol is specialized:

  • Mandatory Flushing: The FDA requires that used or unused Fentanyl patches and certain rapid-acting tablets be immediately flushed down the toilet to prevent accidental exposure.
  • Pre-Disposal Step: Used patches must be folded firmly adhesive-to-adhesive before flushing.
  • Alternative: If a product is not on the flush list, use an authorized Drug Take-Back Program or follow instructions for disposal in household trash by mixing with an undesirable substance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Avaric found in:

A-Z Index: